Critical Comparison: Jaguar Animal Health (JAGX) & The Competition

Jaguar Animal Health (NASDAQ:JAGX) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Jaguar Animal Health to related companies based on the strength of its valuation, risk, analyst recommendations, earnings, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Jaguar Animal Health and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Jaguar Animal Health	$11.51 million	-$53.43 million	-0.00
Jaguar Animal Health Competitors	$5.44 billion	$3.22 billion	552.59

Jaguar Animal Health’s peers have higher revenue and earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Jaguar Animal Health has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Jaguar Animal Health’s peers have a beta of -3.79, meaning that their average stock price is 479% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Jaguar Animal Health and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1	0	0	0	1.00
Jaguar Animal Health Competitors	7798	13891	25790	1038	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.66%. Given Jaguar Animal Health’s peers stronger consensus rating and higher probable upside, analysts plainly believe Jaguar Animal Health has less favorable growth aspects than its peers.

Profitability

This table compares Jaguar Animal Health and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-187.88%	N/A	-131.45%
Jaguar Animal Health Competitors	-2,380.39%	-218.78%	-15.59%

Insider & Institutional Ownership

12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.1% of Jaguar Animal Health shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Jaguar Animal Health peers beat Jaguar Animal Health on 10 of the 13 factors compared.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.